Literature DB >> 10985955

Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA.

N Lan1, B L Rooney, S W Lee, R P Howrey, C A Smith, B A Sullenger.   

Abstract

Recent reports have demonstrated that trans-splicing ribozymes can be employed to repair mutant RNAs. One key factor that influences RNA repair efficiency is the accessibility of the substrate RNA for ribozyme binding, which is complicated by the fact that RNAs may assume multiple conformations and have proteins bound to them in vivo. Here we describe a strategy to map accessible sites on sickle beta-globin (beta(s)-globin) transcripts in vitro and in vivo and to use this information to enhance RNA repair efficiency. Two sites upstream of the sickle mutation were identified as accessible in some fraction of the beta-globin RNA by mapping with a ribozyme library and the accessibility of those sites was assessed by in vitro cleavage analyses. Ribozymes targeting either site could only convert a certain fraction of the beta(s)-globin RNA to product but not drive the reaction to completion. However, cleavage and splicing reactions were driven further toward completion when the two ribozymes were both added to the reactions, suggesting that the substrate RNA is present in multiple conformations in vitro. These two ribozymes were each able to repair beta(s)-globin transcripts in erythrocyte precursors derived from peripheral blood from individuals with sickle cell disease. Moreover, the relative accessibility of the targeted sites in vivo is as predicted by mapping and in vitro analyses. These results demonstrate that this novel RNA mapping strategy represents an effective means to determine the accessible regions of target RNAs and that combinations of trans-splicing ribozymes can be employed to enhance RNA repair efficiency of clinically relevant transcripts such as beta(s)-globin RNA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985955     DOI: 10.1006/mthe.2000.0125

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  9 in total

1.  Functional repair of a mutant chloride channel using a trans-splicing ribozyme.

Authors:  Christopher S Rogers; Carlos G Vanoye; Bruce A Sullenger; Alfred L George
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 2.  Ribozyme-mediated revision of RNA and DNA.

Authors:  Meredith B Long; J P Jones; Bruce A Sullenger; Jonghoe Byun
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

3.  Optimization of trans-splicing ribozyme efficiency and specificity by in vivo genetic selection.

Authors:  Brian G Ayre; Uwe Köhler; Robert Turgeon; Jim Haseloff
Journal:  Nucleic Acids Res       Date:  2002-12-15       Impact factor: 16.971

4.  Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes.

Authors:  Jonghoe Byun; Ning Lan; Meredith Long; Bruce A Sullenger
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

5.  Computational prediction of efficient splice sites for trans-splicing ribozymes.

Authors:  Dario Meluzzi; Karen E Olson; Gregory F Dolan; Gaurav Arya; Ulrich F Müller
Journal:  RNA       Date:  2012-01-24       Impact factor: 4.942

6.  An in vivo selection method to optimize trans-splicing ribozymes.

Authors:  Karen E Olson; Ulrich F Müller
Journal:  RNA       Date:  2012-01-24       Impact factor: 4.942

7.  The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Authors:  Jay N Lozier; Amalia Dutra; Evgenia Pak; Nan Zhou; Zhili Zheng; Timothy C Nichols; Dwight A Bellinger; Marjorie Read; Richard A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

8.  Modification of globin gene expression by RNA targeting strategies.

Authors:  Tong-Jian Shen; Heather Rogers; Xiaobing Yu; Felix Lin; Constance T Noguchi; Chien Ho
Journal:  Exp Hematol       Date:  2007-08       Impact factor: 3.084

9.  Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; Tiffany A Kolniak; Lowell G Sheflin; R Thomas Taggart; Heba E Abdelmaksoud
Journal:  J Ophthalmol       Date:  2011-06-30       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.